UBS initiated coverage of Alvotech (ALVO) with a Buy rating and $18 price target Alvotech is a pure-play biosimilar company, with a ...

The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

Humira revenues were $8.99bn ... We are forecasting an operating margin ratio of roughly 44.5% of sales and model a non-GAAP tax rate of approximately 13.8%. We expect adjusted earnings per ...

Skyrizi sales beat the Zacks Consensus Estimate of $3.58 billion and our model estimate of $3.56 billion. AbbVie’s flagship product Humira recorded a sales decline of 48.7% to $1.68 billion in ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...

This leap enabled systems like ChatGPT and Llama to dominate the AI landscape. However, the rise of AI model aggregators is now bringing long-overdue attention to the broader ecosystem, streamlining ...

As biosimilar competition intensifies, Humira's market share is expected to ... provides easy-to-follow model portfolios designed for wealth accumulation. Curious if ABBV is one of these AI ...

CAMBRIDGE, Mass., Jan. 29, 2025 /PRNewswire/ -- Concerto Biosciences®, a clinical-stage biotech company developing microbial products for therapeutics and consumer markets, today announced the ...